Key facts
- Zealand Pharma stock surged on positive Phase 3 trial results for survodutide.
- Survodutide is a drug candidate for obesity treatment.
- The trial met its primary endpoints.
- Participants achieved substantial weight loss.
Zealand Pharma's stock price saw a notable increase today after the company announced encouraging outcomes from its Phase 3 clinical trial for survodutide, a drug candidate being developed for the treatment of obesity. The trial successfully met its primary objectives, demonstrating significant weight loss among the participants. This positive development is a key milestone for the company's pipeline and its potential entry into the highly competitive obesity market.